Benefits of Fisetin

Evidence-Based Benefits

• Senolytic activity — Yousefzadeh et al. (2018) screened 10 flavonoids and identified fisetin as the most potent natural senolytic, selectively killing senescent cells while sparing healthy cells in both human and mouse tissues
• Lifespan extension — in the same study, fisetin administered to 85-week-old mice (equivalent to ~75 human years) extended median remaining lifespan by approximately 10% and reduced senescence biomarkers in multiple tissues
• Anti-inflammatory — fisetin reduces SASP factors (IL-6, IL-8, MCP-1, TNF-α) secreted by senescent cells, which drive age-related chronic inflammation and tissue dysfunction
• Neuroprotection — preclinical studies show fisetin maintains cognitive function in Alzheimer's models by reducing neuroinflammation, oxidative stress, and amyloid-beta pathology (Currais et al., 2014)
• Antioxidant — fisetin directly scavenges reactive oxygen species and upregulates endogenous antioxidant enzymes including glutathione, catalase, and superoxide dismutase

What the Research Says

Fisetin is a flavonoid that has garnered attention for its diverse health benefits. It was identified as a senotherapeutic agent in a study by Yousefzadeh et al. (2018), where it demonstrated significant clearance of senescent cells both in vitro and in vivo, leading to extended late-life lifespan in mice. Additionally, fisetin has shown neuroprotective effects through its modulation of p25 and inflammatory pathways, as reported by Currais et al. (2014), which maintained cognitive function in Alzheimer's disease transgenic mice.

Recent systematic reviews have further elucidated fisetin's potential across various therapeutic areas. Jiang et al. (2023) reviewed evidence highlighting its neuroprotective effects across multiple neurological diseases, while Prem et al. (2022) analyzed 15 studies and concluded that fisetin reduces oxidative stress and inflammation in myocardial ischemia-reperfusion injury, though its efficacy may depend on dosage and comorbidities.

Despite its promising properties, fisetin's poor oral bioavailability remains a challenge. However, Krishnakumar et al. (2022) reported that novel formulations, such as hybrid-hydrogel, could enhance its bioavailability and pharmacokinetics, potentially overcoming this limitation.

Ongoing clinical trials, including the Mayo Clinic AFFIRM trial, are exploring fisetin's efficacy in elderly women with frailty markers, while other studies investigate its role in improving physical function in breast cancer survivors (Ji et al., 2026). These developments underscore fisetin's potential across multiple therapeutic areas, with continued research focusing on optimizing its delivery and expanding its clinical applications.

Related Conditions